The announcement of upcoming Phase 3 trial readouts is a critical event for biopharmaceutical companies like NewAmsterdam Pharma. Positive results from these trials could lead to drug approvals and commercialization, which would have a significant positive impact on the company's revenue and stock price. The company's statement of being well-capitalized suggests financial stability, which is reassuring for investors and could lead to a positive short-term impact on the stock price.